Free shipping on all orders over $ 500

Dargistotug

Cat. No. M54528
Dargistotug Structure
Synonym:

M-6223

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Dargistotug is a fully human IgG1 monoclonal antibody targeting T-cell immunoglobulin and the ITIM structural domain (TIGIT) that induces an immune response targeting cancer cells by blocking the TIGIT pathway.

Chemical Information
CAS Number 2649362-29-6
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Related TIGIT Products
Tamgiblimab

Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects.

Domvanalimab

Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer.

Ociperlimab

Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.

Vibostolimab

Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

Tiragolumab

Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors.

  Catalog
Abmole Inhibitor Catalog




Keywords: Dargistotug, M-6223 supplier, TIGIT, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.